$RAPP

Rapport Therapeutics COO Gault sells $281k in stock

Rapport Therapeutics COO Cheryl Gault sold 10,000 shares of common stock for a total of $281,857 on March 30, 2026, under a pre-arranged trading plan. This sale occurred after a significant 176% surge in the company's stock over the past year. The company recently announced positive fiscal year 2025 earnings and advanced timelines for Phase 3 studies of RAP-219, leading several analysts to reiterate their Buy ratings with increased price targets.

Original reporting
Investing.com · Investing.com
Published Apr 1, 2026, 3:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 1, 2026, 3:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Rapport Therapeutics COO Gault sells $281k in stock — source image
Decision brief

The 30-second read

$RAPPNeutralLow
01

Why it matters

The insider sale is unlikely to impact the company's positive trajectory significantly, given the pre-arranged nature and supporting fundamentals.

02

Market read

Company-specific news with limited broader market impact.

03

What to watch

Insider sales can be routine and not necessarily indicative of future performance; broader market conditions should also be considered

Timing: Moderate; insider sales can signal caution but are not definitive

Background

Rapport Therapeutics has recently reported positive fiscal results and advanced clinical trial timelines, boosting investor confidence.

Company-level read

Ticker impact

$RAPPNeutralMedium confidence
Context

Recent insider stock sale amid positive company developments

Expected impact

Minimal short-term price movement expected

Evidence & confidence

The insider sale was pre-arranged and coincides with positive company news, suggesting it may not reflect negative outlook but rather personal financial planning. The stock's recent surge and positive earnings support a stable outlook.

Market effects

Potentially positive for biotech/life sciences sector due to company advancements

Limited; company-specific news

Low; focused on company fundamentals

Counterpoint

The insider sale might indicate upcoming negative news or profit-taking after a surge, warranting caution

Key entities

  • Rapport Therapeutics

    Biotech firm focused on neurological disorders.

Related articles

$RAPPMed

Rapport Therapeutics, Inc. (RAPP): Results of Operations and Financial Condition

Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rapp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients RAP-219 Phase 2 trial in b

$BKRMed

Baker Hughes extends long-term service deal for Nigeria LNG Train 7

Baker Hughes said it won a 13-year lifecycle services deal with Nigeria LNG for turbomachinery at NLNG’s Train 7 expansion on Bonny Island. The scope covers heavy-duty gas turbines, centrifugal compressors, remote monitoring via Baker Hughes’ digital platform, and local support. Train 7 is expected to raise capacity from 22 to 30 MMtpa.

$BKRMed

Baker Hughes wins subsea systems contract for Angola's Greater PAJ field

Baker Hughes said it won a contract from Azule Energy to supply subsea production systems for the Greater PAJ ultra-deepwater project offshore Angola. Scope includes horizontal subsea trees, control modules, workover control systems and related equipment plus installation and support. Greater PAJ is expected to start producing in 2029 via an FPSO processing up to 95,000 bpd, with deliveries starting in 2027.

$WENMed

57-year-old Burger chain closed 28 restaurants, 100s more coming

Wendy’s (WEN) said it closed 28 restaurants and expects to close 5% to 6% of U.S. units (about 289 to 358) in 1H 2026, with possible additional selective closures. The company reported 2Q FY2026 systemwide sales down 6.5% YoY, U.S. systemwide down 8.2%, and U.S. same-restaurant sales down 7%. Wendy’s launched a turnaround plan and withdrew its 2026 outlook.

$ACIMed

Albertsons recalls ready-to-eat items in multiple states amid salmonella-linked jalapeño investigation

Albertsons Companies said it is voluntarily recalling four ready-to-eat products containing jalapeños supplied by Taylor Farms, including items sold at Randalls in Texas. The recall followed a supplier recall tied to an ongoing federal investigation and an FDA probe of a Salmonella Javiana outbreak. FDA reported 345 illnesses in 27 states, 36 hospitalizations, no deaths.